Business Wire

MANIV

4.4.2024 17:21:27 CEST | Business Wire | Press release

Share
Maniv Announces Third Early-stage Venture Fund of $140m to Accelerate the Decarbonization and Digitization of Global Transportation

Maniv, a global venture capital firm based in Tel Aviv and NYC, today announces the closing of its third fund, an $140m vehicle to invest in Seed and Series A stage startups that brings the firm’s assets under management to nearly $320m.

Investing since 2016, Maniv was among the first institutional investors to articulate a global, early-stage investment strategy focused on the intersection between mobility, transportation and energy. Maniv invests in deep technologies and business model innovations around two central themes:

The movement of people and goods continues to be marked by analog processes and data-poor operating environments. From manufacturing to fulfillment and logistics, vehicle access, maintenance and repair, insurance, fleet management, and more, startups are driving the digitization of transportation’s value chains across land, sea, and air. Simultaneously, the market-driven decarbonization of transportation – representing as much as one quarter of global GHG emissions – is at an inflection point. Private sector incentives are tipping towards clean propulsion, a process accelerated by brisk regulatory tailwinds worldwide. These seismic shifts create a massive opportunity for startups to advance new technologies, form factors, business models, and platforms.

Maniv has already made four investments out of the new fund. Celadyne, based in Chicago, extends the lifespan and efficiency of proton-exchange membranes to make green hydrogen production financially viable. Neologic, based in Israel, introduces a proprietary chip design for dramatic performance and power gains in data centers, automotive and beyond. Circular, based in San Francisco, mainstreams post-consumer recycled plastics adoption in manufacturing, by closing pervasive information and testing gaps. Vammo, based in São Paulo, is electrifying LATAM’s B2B two-wheeler market, by orchestrating vehicles, financing, and a ubiquitous battery swapping network.

From its first two, top-performing funds, Maniv led investments in breakout companies including AI edge silicon scaleup Hailo from Tel Aviv, EV ridehail and charging network Revel from New York, medium-duty EV truckmaker Harbinger Motors from Los Angeles, intercity bussing platform Kolors from Mexico City, two-wheeler EV OEM River from Bangalore, and Madrid-based car subscription startup Bipi, acquired by Renault’s financing arm RCI Banque in 2021.

Maniv’s third fund is backed by institutional capital, high-net-worth individuals, and a consortium of industry leaders at the forefront of the transportation sector. Maniv’s prior funds were substantially backed by leading carmakers and Tier-1 suppliers. Maniv III maintains those automotive partnerships – including return investors Valeo and InMotion Ventures, the investment arm of Jaguar-Land Rover, joined by Woven Capital of Toyota Motor Corp. The new fund has expanded its LP base to reflect critical automotive adjacencies through partners including global vehicle leasing and mobility solutions leader Arval and the automotive finance experts of BNP Paribas Personal Finance of Europe’s leading bank BNP Paribas; Shell Ventures of the global energy giant Shell; global sustainable infrastructure leader Ferrovial; Enterprise Mobility Ventures, the VC arm of Enterprise Mobility; industrial manufacturing leader ITT Inc.; fleet payments leader WEX; a major European insurance company; several major automotive dealer and distributor groups; and more.

“Our third fund builds on two decades in the trenches of the global mobility ecosystem,” said Michael Granoff, the firm’s Managing Partner. “Maniv has built a platform to summon the best of two worlds – the agility of a traditional VC, and close proximity to the underlying industries surrounding mobility and transportation. We believe we are uniquely structured to leverage our deep institutional memory and access to industry decision-makers, for the benefit of our portfolio companies and ultimately our investors. Announcing this new vehicle amidst a backdrop of geopolitical uncertainty and shaky private markets is a testament to the resilience of the sector and our strategy.”

“Maniv’s mandate is to deliver outsized returns by joining forces with those rare entrepreneurs with both the vision and tenacity to drive the transportation sector into the 21st century,” added Nate Jaret, General Partner at Maniv. “Human prosperity depends on the seamless and sustainable movement of people and goods; mobility continues to represent a generational opportunity for entrepreneurs and investors alike.”

“When we met Maniv, we had spoken to over 100 investors and operators of electric mobility around the world and nobody – repeat nobody – was more knowledgeable about the space than the Maniv team,” said Jack Sarvary, Co-founder & CEO of portfolio company Vammo based in São Paulo. “Getting them not just onto our cap table but also our board quickly became a priority.”

"From the outset it was clear that Maniv is deeply connected to forward-thinking mobility players,” said Ian Arthurs, Founder & CEO of portfolio company Circular. “Within weeks of our first conversation, the Maniv team found us new enterprise partners and customers in the auto space, which would have taken us months to figure out on our own.”

Website: www.maniv.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404972652/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye